Pradzhisan – progestin, corpus luteum hormone. By binding to receptors on the surface of cells Organs, it enters the nucleus, where it activates DNA promotes RNA synthesis. Promotes the transition of the uterine mucosal proliferation phase induced follicular hormone in the secretory phase, and after fertilization – a condition necessary for the development of the fertilized ovum. Decreases Uterine contractility and excitability of muscle and fallopian tubes, stimulates the development of breast end elements. Stimulating proteinlipazu increases fat reserves, promote glucose utilization, increasing the concentration of basal and stimulated insulin promotes the accumulation of glycogen in the liver, increases the production of aldosterone; in small doses, faster, and more – suppresses the production of gonadotropic hormones of the pituitary; reduces azotemia, increases the excretion of nitrogen in urine. Activates the growth of secretory department of acini of the mammary glands and induces lactation. Contributes to the development of normal endometrium.
San Pharmaceutical Industries Ltd, India
For women planning a pregnancy for post-menopausal women, adults prescribed by a doctor for women of childbearing age for women in menopause, women
1 capsule contains:
Active substance: progesterone 200 mg;
Other ingredients: peanut butter, soy lecithin
From mastitis, in menopause, premenstrual syndrome, menstrual disorders by
disorders associated with progesterone deficiency.
The oral route of administration:
- infertility due to luteal insufficiency;
- premenstrual syndrome;
- violations of the menstrual cycle due to ovulation disorders or anovulation;
- fibrocystic breast disease;
- hormone replacement therapy perimenopausal and postmenopausal (in combination with estrogen-containing drugs).
The vaginal route of administration:
- hormone replacement therapy in the case of progesterone deficiency during non-functioning (absent) ovaries (egg donation);
- Support of the luteal phase in preparation for in vitro fertilization;
- Support of the luteal phase in the spontaneous or induced menstrual cycle;
- premature menopause;
- hormone replacement therapy (in combination with estrogenic agents);
- infertility due to luteal insufficiency;
- prevention of habitual abortion and threatened due to lack of progestin;
- prevention of uterine fibroids;
- prevention of endometriosis.
For oral and vaginal application
- thrombophlebitis, thromboembolic disorders, intracranial hemorrhage, or the availability of data states in history;
- bleeding from the genital tract of unknown origin;
- incomplete abortion;
- or suspected malignancy of breast or genital organs;
- hypersensitivity to the drug, including to peanut butter, soy.
For oral application (optional)
Severe liver disease is currently (including cholestatic jaundice, hepatitis, hepatocellular carcinoma, Dubin-Johnson syndrome, Rotor) or history, if liver function tests have not returned to normal.
With care should be prescribed for diseases of the cardiovascular system, hypertension, chronic renal failure, diabetes, asthma, epilepsy, migraine, depression, hyperlipoproteinemia.
In the oral route of administration
Bleeding “breakthrough” or a shortening of the normal menstrual cycle, the tension of the mammary glands (usually in the first month of treatment).
Drowsiness, transient dizziness (usually after 1-3 h after administration), and nausea. These side effects can be reduced by lowering the dose of the drug receiving mode change or transition to the vaginal route of administration. These effects are usually the first signs of an overdose.
The feeling of fatigue, migraine, headache, skin rash, itching, jaundice, fluid retention.
In the oral and vaginal route of administration
Allergic reactions (urticaria, anaphylactic shock).
How to accept, acceptance rate and dosage
The capsules injected deep into the vagina.
The absolute progesterone deficiency in women with non-functioning (absent) ovaries (egg donation) on the background of estrogen therapy on 200 mg / day in the 13 and 14th days of the cycle, followed by 100 mg 2 times / day from the 15th of 25-day cycle, a 26-th day, and in the case of establishing pregnancy dose increases to 100 mg / day every week, reaching a maximum of 600 mg / day, divided into 3 doses. This dose can be used for 60 days.
Support of the luteal phase in preparation for in vitro fertilization: It is recommended to take 200 to 600 mg / day starting from the day of the injection of human chorionic gonadotropin for I and II trimesters of pregnancy
Support of the luteal phase in the spontaneous or induced menstrual cycle, infertility associated with impaired function of the corpus luteum is recommended to take 200-300 mg / day, starting from the 17th day of the cycle for 10 days, in case of delay in menstruation and pregnancy diagnosis treatment should be continued.
In the case of abortion threat or for prevention of habitual abortions occurring against a background of progesterone deficiency: 200-400 mg daily in 2 divided doses in I and II trimesters of pregnancy
At temperatures below 25 ° C
When administered orally
Prolonged simultaneous use of barbiturates, carbamazepine, hydantoin or rifampicin may reduce the effectiveness of progesterone.
Despite the limited data, it is assumed that the activated carbon and griseofulvin can also reduce the effectiveness of the drug.
Progesterone may enhance therapeutic, pharmacological or toxic effects of cyclosporin, theophylline and troleandomycin.
When vaginal application
Cooperation in intravaginal application is not evaluated. Avoid other intravaginal simultaneous administration of drugs to avoid the potential release and absorption of progesterone.
The drug should not be used for contraception.
With long-term treatment of progesterone is necessary to conduct medical examinations (including liver function tests); treatment is necessary to cancel the deviation in the case of diagnostic tests of liver function, or the occurrence of cholestatic jaundice. In the application of estrogen and / or progestogen-containing preparations have been cases of chloasma, especially in patients with a history of chloasma during previous pregnancy. Women with a tendency to develop chloasma, exposure to natural or artificial skin to UV radiation can cause or exacerbate chloasma.
It is necessary to monitor patients with a history of depression, and in the case of severe depression, you need to remove the drug. Patients with concomitant cardiovascular disease or the presence of their history should also be observed periodically physician.
In the treatment of progesterone may experience fluid retention, which can affect the course of epilepsy, migraine, asthma, cardiac or renal failure; such patients should be monitored closely.
Effects on ability to drive vehicles and management mechanisms
When taken orally must be careful when driving and occupation of other potentially hazardous activities that require high concentration and psychomotor speed reactions.
Pregnancy and lactation
Use of the drug Pradzhisan during pregnancy is not contraindicated. Nevertheless, there is a potential risk to the fetus (especially males) in the application of progesterone in the first 4 months of pregnancy. Use of micronized progesterone in the II-III trimester of gestation may lead to the development of liver disease in pregnant women. Numerous epidemiological studies have found no cases of fetal abnormalities when using progesterone in pregnancy.
Progesterone passes into breast milk. Information on the use of the drug during lactation is not sufficient to assess the potential risk to the baby.
Symptoms: drowsiness, transient dizziness, shortening of the normal menstrual cycle
Treatment: dose reduction or correction of the reception mode, for example, in the case of drowsiness and dizziness – 200 mg taken at night from the 12th to the 14th day of the cycle or go on vaginal route of administration: in the case of shortening of the menstrual cycle – start treatment later in the cycle, such as from the 19th day instead of the 17th. If necessary, symptomatic treatment.